Monday, May 06, 2024 11:53:18 AM
wake up to the fraud. Pigeon posters can't turn that around as much as their bosses would like it to which in my opinion is
comprised of some our own 13D. Now is this sabotage legal? Go Sidley, there is much to discover if you haven't already.
The truth always has a way of being revealed. TIK TOK pigeons. $CYDY$ 2024 Leronlimab, the one that should have been granted EUA but for some pig pharma biased scoundrels at the FDA as we saw by their emails.... what else will legal eagle Sidley uncover as we pick apart AmarX??
BioNTech’s total revenue in the first quarter of 2024 nosedived to around $202 million, a sharp decline from nearly $1.38 billion during the same time period last year, the German biotech reported on Monday.
BioNTech suffered a net loss of almost $340 million during Q1, or $1.41 per share. Analysts had expected a $0.78 drop in earnings per share (EPS), according to stocks analysis firm Zacks Investment Research. By comparison, in Q1 of 2023, BioNTech reported a net profit of approximately $541 million, or $2.21 per share.
The company attributed the plunge in the latest quarter to “lower commercial revenues” from the sales of its COVID-19 vaccine worldwide, which it said was largely driven by the “endemic-level demand” for the shot.
Also contributing to the biotech’s net loss was a more aggressive investment strategy in research and development. BioNTech pumped around $546 million into its R&D activities, up from nearly $360 million during the same period last year. The increase in spending was due to progressing clinical studies and a larger workforce, resulting in greater wage, benefits and social security expenses.
Despite a steep drop in its Q1 revenue, CEO Ugur Sahin struck a positive note in the company’s statement on Monday, focusing instead on BioNTech’s pipeline and upcoming milestones.
“In the past weeks, we have reported positive preliminary data for both our individualized and off-the-shelf mRNA-based candidates,” which further demonstrate the strong potential of the biotech’s core technologies, Sahin said. For 2024, BioNTech plans to develop a variant-adapted COVID-19 vaccine, as well as advance its cancer programs, paying particular focus on its bispecific antibody and antibody-drug conjugate (ADC) assets.
Seeking to establish its footing in a post-COVID-19 world, BioNTech has upped its investments in oncology as a way to diversify its business. In October 2023, the biotech inked a potential $1 billion deal with Suzhou-based biotech MediLink Therapeutics to develop next-generation ADCs targeting the HER3 protein.
BioNTech in February 2024 also entered into a $250 million licensing and manufacturing agreement with Autolus Therapeutics to advance investigational CAR-T therapies for solid tumors.
Looking ahead to the rest of the year, BioNTech forecasts total group revenue of $2.69 billion to $3.34 billion. The company on Monday said that nearly all its expected 2024 revenues would come in at the end of the year. As of March 31, 2024, BioNTech had almost $18.25 billion in cash, cash equivalents and security investments.
Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM